Immix Biopharma reports 89% interim response rate in NEXICART-2

Immix Biopharma said its interim update across all NEXICART-2 patients showed an 89% complete response rate, with MRD-negativity suggesting potential to reach up to a 98% complete response rate, supporting potential best-in-class therapy for relapsed/refractory AL amyloidosis.